Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Neily Zakiyah, Rano K Sinuraya, Arif S W Kusuma, Auliya A Suwantika & Keri Lestari. (2021) Cost-Effectiveness Analysis of Sacubitril/Valsartan Compared to Enalapril for Heart Failure Patients in Indonesia. ClinicoEconomics and Outcomes Research 13, pages 863-872.
Read now
Read now
Lin Liang, David Bin-Chia Wu, Mohamed Ismail Abdul Aziz, Raymond Wong, David Sim, Kui Toh Gerard Leong, Yong Quek Wei, Doreen Tan & Kwong Ng. (2018) Reply: Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction. Journal of Medical Economics 21:12, pages 1148-1149.
Read now
Read now
Joaquim Cristino, Immanuel Tang, Caroline Ng, Jonathan Tan, David Trueman & Declan Lee. (2018) RE: Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction. Journal of Medical Economics 21:12, pages 1145-1147.
Read now
Read now
Articles from other publishers (13)
Ramin Ravangard, Farideh Sadat Jalali, Marjan Hajahmadi & Abdosaleh Jafari. (2023) Cost-utility analysis of valsartan, enalapril, and candesartan in patients with heart failure in Iran. Health Economics Review 13:1.
Crossref
Crossref
Ratih P. Febrinasari, Stefanus E. Putra, Muhammad Hafizhan & Ari N. Probandari. (2022) Cost-Effectiveness of Sacubitril–Valsartan Compared to Angiotensin-Converting Enzyme Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction. Journal of Pharmacy Practice 36:4, pages 915-924.
Crossref
Crossref
Clare Proudfoot, Raju Gautam, Joaquim Cristino, Rumjhum Agrawal, Lalit Thakur & Keith Tolley. (2022) Model parameters influencing the cost-effectiveness of sacubitril/valsartan in heart failure: evidence from a systematic literature review. The European Journal of Health Economics 24:3, pages 453-467.
Crossref
Crossref
Yake Lou, Tianyang Hu & Jing Huang. (2022) Cost-Effectiveness of Adding Empagliflozin to Standard Treatment for Heart Failure with Preserved Ejection Fraction Patients in China. American Journal of Cardiovascular Drugs 23:1, pages 47-57.
Crossref
Crossref
Rasha Kaddoura, Dina Abushanab, Abdul Rahman Arabi, Sumaya Alsaadi Alyafei & Daoud Al-Badriyeh. (2022) Cost-Effectiveness Analysis of Sacubitril/Valsartan for Reducing the Use of Implantable Cardioverter-Defibrillator (ICD) and the Risk of Death in ICD-Eligible Heart Failure Patients with Reduced Ejection Fraction. Current Problems in Cardiology 47:12, pages 101385.
Crossref
Crossref
Audrey Huili Lim, Nusaibah Abdul Rahim, Jinxin Zhao, S. Y. Amy Cheung & Yu-Wei Lin. (2022) Cost effectiveness analyses of pharmacological treatments in heart failure. Frontiers in Pharmacology 13.
Crossref
Crossref
Chia-Te Liao, Chun-Ting Yang, Fang-Hsiu Kuo, Mei-Chuan Lee, Wei-Ting Chang, Hsin-Ju Tang, Yi-Ming Hua, Hung-Yu Chang, Zhih-Cherng Chen, Carol Strong, Huang-Tz Ou & Han Siong Toh. (2021) Cost-Effectiveness Evaluation of Add-on Empagliflozin in Patients With Heart Failure and a Reduced Ejection Fraction From the Healthcare System's Perspective in the Asia-Pacific Region. Frontiers in Cardiovascular Medicine 8.
Crossref
Crossref
Xiao-qi Liu, Li-shan He, Jian-qing Huang, Ling-juan Xiong, Chen Xia & Hai-yan Lao. (2020) Cost-effectiveness analyses of sacubitril-valsartan for heart failure. Heart Failure Reviews 26:5, pages 1119-1130.
Crossref
Crossref
Rafael Perera, Richard Stevens, Jeffrey K Aronson, Amitava Banerjee, Julie Evans, Benjamin G Feakins, Susannah Fleming, Paul Glasziou, Carl Heneghan, FD Richard Hobbs, Louise Jones, Milena Kurtinecz, Daniel S Lasserson, Louise Locock, Julie McLellan, Borislava Mihaylova, Christopher A O’Callaghan, Jason L Oke, Nicola Pidduck, Annette Plüddemann, Nia Roberts, Iryna Schlackow, Brian Shine, Claire L Simons, Clare J Taylor, Kathryn S Taylor, Jan Y Verbakel & Clare Bankhead. (2021) Long-term monitoring in primary care for chronic kidney disease and chronic heart failure: a multi-method research programme. Programme Grants for Applied Research 9:10, pages 1-218.
Crossref
Crossref
Younan Yao, Rongcheng Zhang, Tao An, Xinke Zhao & Jian Zhang. (2020) Cost‐effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China. ESC Heart Failure 7:6, pages 3582-3592.
Crossref
Crossref
Yue Wu, Shuo Tian, Peipei Rong, Fan Zhang, Ying Chen, Xianxi Guo & Benhong Zhou. (2020) Sacubitril-Valsartan Compared With Enalapril for the Treatment of Heart Failure: A Decision-Analytic Markov Model Simulation in China. Frontiers in Pharmacology 11.
Crossref
Crossref
Michele Correale, Ilenia Monaco, Armando Ferraretti, Lucia Tricarico, Giuseppina Padovano, Ennio Sascia Formica, Valeria Tozzi, Davide Grazioli, Matteo Di Biase & Natale Daniele Brunetti. (2019) Hospitalization cost reduction with sacubitril-valsartan implementation in a cohort of patients from the Daunia Heart Failure Registry. IJC Heart & Vasculature 22, pages 102-104.
Crossref
Crossref
Rungroj Krittayaphong & Unchalee Permsuwan. (2018) Cost-Effectiveness Analysis of Sacubitril-Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction in Thailand. American Journal of Cardiovascular Drugs 18:5, pages 405-413.
Crossref
Crossref